Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Lorus grosses $Cdn28mm through public offering

Executive Summary

Oncology company Lorus Therapeutics Inc. grossed $Cdn28mm ($25.4mm) through the public offering of 56.5mm shares (including partial exercise of the overallotment) at $Cdn0.50. Lorus intends to use some of the proceeds to continue Phase I trials of lead compound LOR253 for non-small cell lung cancer, as well as to fund early studies of the project for acute myeloid leukemia and other blood cancers.
Deal Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies